Anticoagulation With Rivaroxaban in a Hematology Unit: Clinical profile, Events and Discontinuation Rates in real-life Patients With Nonvalvular Atrial Fibrillation

References

• Kirchhof P , BenussiS, KotechaDet al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS . Eur. Heart J.37 ( 38 ), 2893 – 2962 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC, CalderónAet al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care . Rev. Esp. Cardiol.67 ( 2 ), 150 – 151 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Marzec LN , WangJ, ShahNDet al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation . J. Am. Coll. Cardiol.69 ( 20 ), 2475 – 2484 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Davies T , GeleitR . Anticoagulation service: improving the referral process . BMJ Qual. Improv. Rep.3, pii:u204229.w1833 ( 2014 ) ( Epub ahead of print ).
   Google Scholar
• Palareti G , AntonucciE, MigliaccioLet al. Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago . Intern. Emerg. Med.12 ( 8 ), 1109 – 1119 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• An J , NiuF, ZhengCet al. Warfarin management and outcomes in patients with nonvalvular atrial fibrillation within an integrated health care system . J. Manag. Care Spec. Pharm.23 ( 6 ), 700 – 712 ( 2017 ).
   PubMedGoogle Scholar
• Challen L , AgbahiweS, CantieriTet al. Impact of point-of-care implementation in pharmacist-run anticoagulation clinics Within a community-owned health system: a two-year retrospective analysis . Hosp. Pharm.50 ( 9 ), 783 – 788 ( 2015 ).
   PubMedGoogle Scholar
• Barnes GD , NallamothuBK, SalesAE, FroehlichJB . Reimagining anticoagulation clinics in the era of direct oral anticoagulants . Circ. Cardiovasc. Qual. Outcomes9 ( 2 ), 182 – 185 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Howard M , LipshutzA, RoessBet al. Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants . J. Thromb. Thrombol.43 ( 2 ), 149 – 156 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Lip GY , NieuwlaatR, PistersR, LaneDA, CrijnsHJ . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation . Chest137 ( 2 ), 263 – 272 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Camm AJ , AmarencoP, HaasSet al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation . Eur. Heart J.37 ( 14 ), 1145 – 1153 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• de la Figuera M , CinzaS, MarínN, EgocheagaI, PrietoMA . Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting. The SILVER-AP study . Aten. Primaria doi:10.1016/j.aprim.2017.05.009 ( 2017 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Carnero Montoro L , Roldán RabadánI, Marín OrtuñoFet al. Differences in the characteristics and management of patients with atrial fibrillation followed-up by cardiologists and other specialists . Rev. Esp. Cardiol. (Engl. Ed.)70 ( 10 ), 883 – 886 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Contreras Muruaga MDM , VivancosJ, ReigGet al. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation . J. Comp. Eff. Res.6 ( 4 ), 303 – 312 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Halperin JL , HankeyGJ, WojdylaDMet al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) . Circulation130 ( 2 ), 138 – 146 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Benedetti G , NecciaM, AgatiL . Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence . Minerva Cardioangiol. doi:10.23736/S0026-4725.17.04553-4 ( 2017 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Yu AYX , MaloS, SvensonLW, WiltonSB, HillMD . Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population-based study . J. Am. Heart Assoc.6 ( 11 ), pii:e007129 ( 2017 ).
   Web of Science ®Google Scholar
• Eikelboom JW , WeitzJI . ‘Realworld’ use of non-vitamin K antagonist oral anticoagulants (NOACs): lessons from the Dresden NOAC Registry . Thromb. Haemost.113 ( 6 ), 1159 – 1161 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Therapeutic Positioning Report UT_ACOD/V5/21112016 . Criteria and general recommendations for the use of direct oral anticoagulants in the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation . ( 2017 ). www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/criterios-anticoagulantes-orales.pdf
   Google Scholar
• Barrios V , EscobarC, PrietoLet al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA study. Estudio PAULA . Rev. Esp. Cardiol.68 ( 9 ), 769 – 776 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Anguita M , BertomeuV, CequierÁ . Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors . Rev. Esp. Cardiol.68 ( 9 ), 761 – 768 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Esteve-Pastor MA , Rivera-CaravacaJM, Roldán-RabadánIet al. Quality of oral anticoagulation with vitamin K antagonists in ‘real-world’ patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry . Europace doi:10.1093/europace/eux314 ( 2017 ) ( Epub ahead of print ).
   Google Scholar
• Björck F , SandénP, RenlundH, SvenssonPJ, SjälanderA . Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden . Thromb. Res.136 ( 2 ), 216 – 220 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Arbring K , UppugunduriS, LindahlTL . Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics . BMC Health Serv. Res.13, 85 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bishop L , YoungS, TwellsL, DillonC, HawboldtJ . Patients’ and physicians’ satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic . BMC Res. Notes8, 233 ( 2015 ).
   PubMedGoogle Scholar
• Camm AJ , FoxKAA, PetersonE . Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention . Europace20 ( 1 ), 1 – 11 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Patel SI , CheringtonC, ScherberRet al. Assessment of patient adherence to direct oral anticoagulant vs warfarin therapy . J. Am. Osteopath. Assoc.117 ( 1 ), 7 – 15 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Castellucci LA , ShawJ, van der SalmKet al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale . Thromb. Res.136 ( 4 ), 727 – 731 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Yao X , AbrahamNS, AlexanderGCet al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation . J. Am. Heart Assoc.5 ( 2 ) ( 2016 ).
   Web of Science ®Google Scholar
• Brown JD , ShewaleAR, TalbertJC . Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention for newly diagnosed and treatment-naive atrial fibrillation patients: an update using 2013–2014 data . J. Manag. Care Spec. Pharm.23 ( 9 ), 958 – 967 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• McHorney CA , AshtonV, LalibertéFet al. Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation . J. Manag. Care Spec. Pharm.23 ( 9 ), 980 – 988 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Patel MR , MahaffeyKW, GargJet al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation . N. Engl. J. Med.365 ( 10 ), 883 – 891 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hecker J , MartenS, KellerLet al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry . Thromb. Haemost.115 ( 5 ), 939 – 949 ( 2016 ).
   PubMed Web of Science ®Google Scholar